Ann: Update on USA Operations, page-105

First 105 Last

Share
Profile

Follow
Taylen

30 Posts.

1

06/09/17

23:38

Post #: 27046974
Share

Originally posted by toesen ↑

I appreciate all the answers and I am fully aware of the deferred revenue not being "bad" and that it helps cash flow enormously.

The problem was the company made a statement where they say the following:

"Therefore, for the year ended 30 June 2017, the revenue recognized for accounting purposes is $9.4m lower than the actual cash collected. The consequence of this conservative revenue recognition treatment is that the cash surplus of $4.2m is reduced to an accounting net loss of $4.2m. In conclusion, the company’s business operations are healthy with a strong and growing operating cash margin."

"Therefore" - BIG use the deferred revenue as the explanation why cash surplus of 4.2 actually shows in accounting as -4.2.

I have no problem with the accounting but with the narrative - in the context, if all expenses/liability on the deferred revenue had been paid in FY17 the explanation would have had looked differently and definitely not being able to state 4.2 as the "result".

It matters in my world because if BIG made 4.2 in FY17 then it is trading at PE 44 and if they made 2.2 the PE is 88. Quite a difference obv.

Since we know the deferred revenue becomes even bigger in FY18 then it would be great to really understand some kind of ratio between deferred revenue and cost of services not yet delivered.

In trying to assess what I think of PE FY18 then I need to understand how profitable BIG actually was in 2017.

Expand

Not sure I quite follow where your going?
They basically said accruals=4.2 loss
Cash basis they would have made a profit.
The expenses incurred will be at the same margin for any other basic operating revenue from BIG so the expenses that are expected won't be a surprise at all??

BIG Price at posting: $1.35 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

There are more pages in this discussion • 120 more messages in this thread...

First 105 Last

Add BIG (ASX) to my watchlist

Ann: Update on USA Operations, page-105

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SPC to merge with Original Juice Co and Nature One Dairy

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Featured News